EGFR突变型手术切除非小细胞肺癌的辅助治疗:综述
本综述聚焦手术切除的EGFR突变阳性非小细胞肺癌辅助治疗。随机3期试验显示辅助EGFR酪氨酸激酶抑制剂(TKI)带来无病生存获益,ADAURA试验评估3年辅助奥希替尼,显示一致的DFS获益及对脑转移发生的显著预防作用。辅助化疗作用、合适疗程、复发管理和有效治愈率仍未确定。
要点
- 随机3期试验显示辅助EGFR TKI在切除的EGFR突变阳性NSCLC中带来DFS获益。
- ADAURA试验评估3年辅助奥希替尼,显示一致DFS获益及对脑转移发生的显著预防作用。
- 辅助化疗作用、合适疗程、复发管理和有效治愈率仍未确定。
核心结论
- 辅助奥希替尼彻底改变了IB-IIIA期手术切除EGFR突变阳性NSCLC的治疗格局。
- 由临床问题驱动的进一步证据将是进一步优化这些患者辅助治疗目标的关键。
研究设计与样本
- 本文为综述,旨在聚焦手术切除EGFR突变阳性NSCLC辅助治疗快速演变的临床实践场景与未来展望。
主要发现
- 随机3期临床试验显示辅助EGFR TKI治疗在手术切除的EGFR突变阳性NSCLC患者中带来无病生存(DFS)获益。
- 最近的ADAURA试验评估3年辅助奥希替尼,显示一致的DFS获益及该干预对预防脑转移发生的显著作用。
- 辅助化疗的作用、合适治疗时长、疾病复发管理及有效治愈率仍未确定。
- 对分子生物标志物、共变模式及术后循环DNA动态监测的深入研究可能有助于实施未来策略以进一步提高EGFR突变阳性NSCLC辅助治疗后的生存率。
关键数值与推荐
- IB-IIIA期切除的非小细胞肺癌(NSCLC)辅助化疗对提高治愈率的获益有限。
- ADAURA试验评估3年辅助奥希替尼,显示一致的DFS获益及对脑转移发生的显著预防作用。
临床怎么用
- 辅助奥希替尼彻底改变了IB-IIIA期手术切除EGFR突变阳性NSCLC的治疗格局。
- 辅助化疗的作用、合适治疗时长、疾病复发管理及有效治愈率仍未确定。
局限性
- 辅助化疗的作用、合适治疗时长、疾病复发管理及有效治愈率仍未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of adjuvant chemotherapy for stage IB-IIIA resected non-small cell lung cancer (NSCLC) has limited benefit for improving cure rates. The proportion of epidermal growth factor receptor (EGFR) alterations among patients with resected NSCLC is comparable to that observed in patients with advanced disease, and the use of EGFR tyrosine kinase inhibitors (TKIs) has been demonstrated to prolong disease-free survival (DFS). With recent approval of osimertinib in this context, a focus on the rapidly evolving scenario and future perspective in clinical practice is needed and was the aim of the current review. OBSERVATIONS: Randomized phase 3 clinical trials demonstrated DFS benefit with adjuvant EGFR TKI therapy in patients with resected EGFR mutation-positive NSCLC. The most recent trial (ADAURA) assessed 3-year adjuvant osimertinib and showed consistent DFS benefit and a significant role of the intervention in preventing the occurrence of brain metastasis. However, the role of adjuvant chemotherapy, the appropriate duration of treatment, the management of disease relapse, and the effective cure rate remain undetermined. A deeper investigation on molecular biomarkers, covariant patterns, and dynamic monitoring of postsurgical circulating DNA would be helpful for the implementation of future strategies to further improve survival rates after adjuvant therapy for EGFR mutation-positive NSCLC. CONCLUSIONS AND RELEVANCE: Adjuvant osimertinib revolutionized the treatment algorithm for patients with stage IB-IIIA resected EGFR mutation-positive NSCLC. Further evidence driven by clinical issues will be key for further optimization of the goals of adjuvant treatment in these patients.
引用
- Passaro A, Mok TSK, Attili I, et al. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review. JAMA Oncol. 2023. PMID: 37166792. doi:10.1001/jamaoncol.2023.0459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。